Article

Analysis of the Clinical Value of Delphian Lymph Node Metastasis in Papillary Thyroid Carcinoma

Qiumei Zuo,1,2 Xin Chen,1,2 Jingyu Yang,1,2 Shuang Qiu,1,2 Yuan Zhao,3 and Jianwei Sun1,2

1Department of Thyroid and Breast Surgery, The First People’s Hospital of Yunnan Province, Kunming, China
2The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650500, China
3Department of Oncology, Puer People’s Hospital, Puer, Yunnan 665000, China

Correspondence should be addressed to Yuan Zhao; duguxiaoting@163.com and Jianwei Sun; 9y140257@kust.edu.cn

Received 16 April 2022; Revised 9 May 2022; Accepted 18 May 2022; Published 10 June 2022

Purpose. Delphian lymph node (DLN) is often involved in metastasis of malignant head and neck tumors. This study evaluates the predictive utility of the DLN and the clinicopathological factors related to DLN metastasis in individuals suffering from papillary thyroid carcinoma (PTC). Patients and Methods. A retrospective analysis was made on 969 PTC patients enrolled from 2017 to 2021. Among these patients, 522 PTC patients are DLN positive and 447 are negative. Comparisons of clinicopathological characteristics between the DLN-positive and DLN-negative patients were made. Results. The DLN was detected in 53.9% (522/969) cases, and DLN metastasis occurred in 20.3% (106/522) cases. The independent predictors of DLN metastasis (DLNM) include tumorsize >1 cm, tumor located in the upper third thyroid or isthmus, central lymph nodemetastasis (CLNM), and lateral lymph node metastasis (LLNM). DLN-positive individuals exhibited a higher incidence and the number of CLNM, contralateral CLNM (CCLNM), and LLNM as compared to DLN-negative patients. Whether it is cN0 or cN+, the CLNM incidence was increased among DLN-positive patients as compared to that of DLN-negative patients. Conclusions. Positive DLN indicated an increased rate and number of metastases in the cervical lymph nodes. Intraoperative rapid freezing is recommended to assess the status of the DLN, and careful assessment of cervical lymph nodes is warranted when the DLN is involved to implement an appropriate surgical approach.

1. Introduction

With the increasing popularization of head and neck ultrasonography (US) in thyroid cancer screening, the number of thyroid cancer patients has increased [1]. The most prevalent thyroid cancer type (>90%) is papillary thyroid carcinoma (PTC) [2, 3]. PTC is a kind of indolent cancer. Its 5-year overall survival (OS) rate can be up to 97%, but 20–80% of early-stage cancer patients exhibit lymph node metastasis, which augments the risk of regional recurrence and affects the overall quality of life [4–7]. The most important method for preoperative assessment of cervical lymph nodes is US, but the sensitivity of preoperative US to detect lateral lymph nodes is only about 30% [8]. Therefore, finding a reliable index to accurately assess the lymph nodes is very important for guiding the scope of thyroid surgery. The Delphian lymph node (DLN), named in honor of the Delphian oracle of ancient Greece [9], is also referred to as the prelaryngeal lymph node and is a central cervical lymph node (CLN), as are the paratracheal and pretracheal nodes. The DLN was first realized in throat and hypopharyngeal cancers, which predicts elevated mortality and recurrence rates. It has received more and more attention because of its unique anatomical position [10, 11]. Recently, some researchers have explored the clinical relevance of the DLN in PTC, demonstrating that DLN metastasis (DLNM) is of a prognostic value in cervical and lateral lymph nodes [12–14]. However, these studies had small sample sizes or reported different clinicopathological factors.
associated with DLNM. In the context of limited studies, the clinical significance of DLN remains controversial.

Here, we explore risk factors that affect DLN metastasis using the large sample size and clarify the correlation between the DLN and cervical lymph nodes to provide a basis for choosing an appropriate scope of surgery for PTC patients.

2. Materials and Methods

2.1. Patients. Clinical and pathological data from 969 PTC patients who underwent the first operation in the Sun Jianwei Medical Group of the Thyroid and Breast Surgery Department of the First People’s Hospital of Yunnan Province from January 2017 to May 2021 were reviewed. The Ethics Committee of Yunnan First People’s Hospital approved this analysis, and all patients signed informed consents. Of the 969 included patients, 522 had DLNs, and the remaining 447 had adipose tissue in the prelaryngeal area. The information collected was as follows: sex, age, tumor size, bilaterality, multifocality, the number of tumors, extrathyroidal extension (ETE), central and lateral lymph nodes of the neck, pathologic types, Hashimoto’s thyroiditis, and cancerous nodules. In the case of multifocality, the largest lesion was measured when judging the tumor size and location.

2.2. Surgery. Bilateral PTC undergoes total thyroidectomy, and patients with unilateral PTC undergo total/near-total thyroidectomy or lobectomy and isthmus resection. Total thyroidectomy may be considered in cases in which unilateral PTC has more than one of the following: tumor size >4 cm, one lobe with multifocality, ETE, or distant metastasis (as per the Chinese Thyroid Association guidelines). Central lymph node dissection (CLND) was routinely conducted in all patients on the affected side, while contralateral CLND was performed when the central lymph node was suspected by preoperative imaging or intraoperative examination. Ipsilateral therapeutic lateral lymph node dissection (LLND) was conducted when suspected cervical lymph nodes were detected by preoperative physical examination, imaging (ultrasound, CT, MRI, and/or PET-CT), fine-needle aspiration cytology (FNAC), and/or intraoperative visual examination. LLND resection included lymph nodes at levels II–V. During this operation, the bilateral thyroid gland lobes were injected using carbon nanoparticles (Chongqing Levin U.S. Pharmaceutical, China, approval number: Zhunzi H20073246), which were lymphatic tracers that can assist in tracing the DLN (Figure 1). Central lymph nodes were routinely removed. Soft fascial tissue above the thyroid isthmus in front of the thyroid and cricoid cartilage was labeled DLN, with remaining central lymph nodes (paratracheal and pretracheal) being labeled CLNs.

2.3. Statistical Analysis. SPSS 26.0 (IBM Analytics, USA) was used to analyze data. Qualitative data were compared via the Pearson χ² test. Fisher’s exact test was used for sample sizes less than 5. For continuous variables, an independent sample t-test is used. Multivariate logistic regression was conducted to estimate DLNM risk factors for all variables significant in univariate analysis. P < 0.05 was the significance threshold.

3. Results

3.1. General Characteristics of DLN. A total of 969 patients were included in this analysis, 522 (53.9%) had the DLN detected. The average number of DLNM was 2, of which 106 (20.3%) had DLNM (Table 1). It is worth noting that 17 (1.7%) patients exhibited only DLNM without central lymph node metastasis. Four cases (10%) showed jump metastasis (LLNM positive and CLN negative). Among the 522 patients with PTC, 408 underwent total thyroidectomy and 114 underwent lobectomy plus isthmus resection. According to the above standards, all patients received CLND and 46 patients received LLND (Table 2).

3.2. Clinical and Pathological Features of DLNM. The clinicopathological characteristics of DLN-positive and DLN-negative groups were initially compared via univariate analysis (Table 3). Males were more common among DLN-positive patients in comparison to DLN-negative patients (27.4% vs. 17.1%, P = 0.016). The proportion of tumor size >1 cm (67.0% vs. 22.6%, P < 0.001) and the tumor location in the upper 1/3 and isthmus (41.8% vs. 27.0%, P = 0.003) was more common among those exhibiting DLN positivity. There was a significant correlation between DLNM and ETE (21.7% vs. 7.5%, P < 0.001), close to the envelope (5.7% vs. 1.4%, P = 0.026), CLNM (84.0% vs. 29.8%, P < 0.001), and LLNM (30.2% vs. 2.2%, P < 0.001). The average maximum size of metastatic lymph nodes was increased among DLN-positive patients relative to those that were DLN-negative (2.71 ± 1.07 vs. 2.12 ± 0.75, P < 0.001). After 0.5 to 5 years of follow-up, four patients (0.77%) had a locoregional
4. Discussion

This analysis retrospectively examined the real-world data of 522 PTC patients. The clinicopathological characteristics pertaining to lymph node metastasis were systematically and comprehensively evaluated. DLN metastases in PTC patients were related to tumor aggressiveness and indicated CLN and LLN metastasis.

DLNM is widely regarded as an indicator of a poor prognosis of head and neck malignancies, particularly PTC. Isaacs et al. found that the DLN was more accurate in predicting cervical lymph node metastasis than paratracheal and pretracheal lymph nodes [15]. In previous studies, the rate of DLN metastasis in PTC patients was 9%-25.4% [16, 17]. In our study, the rate of DLNM was 20.3%, which aligns with other studies. Cervical lymph node metastasis can predict recurrence. Those individuals with more or larger lymph node metastasis have a significantly higher risk of recurrence [18–20]. In our study, the numbers and rates of CLNM and LLNMs were elevated in DLN-positive patients than those without such metastases and the proportion of metastatic CLNs greater than 5 was higher. Moreover, metastatic LNs were larger on average among DLN-positive patients in comparison to those that were DLN-negative. Sugitani et al. also found lymph node metastases larger than 3 cm to be related to disease-specific survival among individuals with PTC [21]. These studies suggest that if DLN metastasis is suspected during surgery, surgeons must fully assess the CLN and LLN status before deciding on the scope of surgery.

The previous study has indicated that DLNM is closely related to tumor size, location, ETE, multifocality, bilaterality, central and lateral cervical lymph node metastasis, and more [22–24]. The clinicopathological factors related to DLNM metastasis were inconsistent in previous reports. Cancer nodules present in lymph nodes of PTC patients are associated with distant metastasis and worse survival outcomes [25]. Here, the appearance of cancer nodules did not differ as a function of the DLN status. Males harboring larger tumors are at a higher risk of DLNM development, and DLNM suggests a higher risk of ETE and close to the capsule and the high incidence of CLNM and LLNM. In addition, tumor size >1 cm, located in the upper 1/3 and isthmus, CLNM, and LLNM were independently associated with DLNM risk. Chai et al. reported that the location of tumors in DLN-positive patients is more likely to be in the isthmus and DLN-negative groups (6.23 ± 4.50 vs. 3.89 ± 2.09, P = 0.142) (Table 7).

3.5. Correlation between DLNM and Clinical N Stage

Table 8 shows the CLNM incidence in the clinical-stage N. cN0: the incidence of CLNM was 32.1%. The incidence of CLNM was significantly elevated among DLN-positive patients relative to those that were DLN-negative (73.5% vs. 26.6%, P < 0.001; 18.4% vs. 6.8%, P = 0.011) in the patients at cN0 or T3/T4 tumors. In cN+ patients, the incidence of CLNM was 93.0% in the DLNM metastasis group and 55.3% in those without the DLN metastasis group (P < 0.001).

3.3. Correlations between DLNM and CLN

In this study, 372 patients underwent unilateral CLND and 150 patients underwent bilateral CLND. In patients with unilateral CLND, the proportion and the number of CLNM were higher among DLN-positive individuals relative to those that were DLN-negative (79.0% vs. 27.1%, P < 0.001; 3.69 ± 2.38 vs. 2.06 ± 1.64, P < 0.001). The same situation also appeared in bilateral CLND (93.0% vs. 37.4%, P < 0.001; 5.90 ± 4.62 vs. 2.95 ± 3.35, P = 0.002). Further analysis revealed that compared with the DLN-negative group, the incidence of CLNM was greater than 5 in the DLN-positive group.

The DLN-positive group was increased relative to DLN-negative patients (unilateral: 28.6% vs. 7.1%, P = 0.01; bilateral: 47.5% vs. 10.0%, P < 0.001) (Table 5)

It is interesting to note that there were 68 cases of total thyroidectomy plus bilateral CLND and postoperative pathological confirmation of unilateral PTC, including 20 cases in the DLN-positive group and 48 cases in the DLN-negative group. The incidence of contralateral CLNM (CCLNM) in the DLN-positive group was higher than that in the DLN-negative group (50.0% vs. 6.3%, P < 0.001). Similarly, for the ipsilateral CLN metastasis, the DLN-positive group was also higher than the DLN-negative group (95.0% vs. 20.8%, P < 0.001) (Table 6).

3.4. Correlation between DLNM and LLN

Forty-six patients underwent LLND, including 42 cases of unilateral LLND with 36 cases of LLM and 4 cases of bilateral LLND with 4 cases of LLNM. Among DLN-positive patients, the incidence of LLNM was higher as compared to DLN-negative patients (93.9% vs. 69.2%, P = 0.045). However, there were no differences in LLNM numbers between the DLN-positive and DLN-negative groups (6.23 ± 4.50 vs. 3.89 ± 2.09, P = 0.142) (Table 7)
Table 2: The extent of surgery in DLN-positive and DLN-negative groups.

| Extent of surgeries                  | DLN-positive (n = 106) | DLN-negative (n = 416) | Total |
|--------------------------------------|------------------------|------------------------|-------|
| Lobectomy plus isthmectomy           | 114                    |                        |       |
| Ipsilateral CLND                     | 15                     | 99                     | 114   |
| Total thyroidectomy                  |                        |                        | 408   |
| Unilateral CLND                      | 34                     | 202                    |       |
| Unilateral CLND and LLND             | 13                     | 8                      | 15    |
| Bilateral CLND                       | 24                     | 102                    | 126   |
| Bilateral CLND and unilateral LLND   | 17                     | 4                      | 21    |
| Bilateral CLND and LLND              | 3                      | 1                      | 4     |

DLN, Delphian lymph node; LLND, lateral lymph node dissection; CLND, central lymph node dissection.

Table 3: DLN clinical and pathological features in univariate analysis.

| Characteristics                        | DLN-positive n (%) | DLN-negative n (%) | P value |
|----------------------------------------|--------------------|--------------------|---------|
| Sex                                    |                    |                    | 0.016   |
| Male                                   | 29 (27.4)          | 71 (17.1)          |         |
| Female                                 | 77 (72.6)          | 345 (82.9)         |         |
| Age                                     |                    |                    | 0.053   |
| ≥55 years                              | 97 (91.5)          | 350 (84.1)         |         |
| <55 years                              | 9 (8.5)            | 66 (15.9)          |         |
| Tumor size                             |                    |                    | <0.001  |
| ≤1 cm                                  | 35 (33.0)          | 322 (77.4)         |         |
| >1 cm                                  | 71 (67.0)          | 94 (22.6)          |         |
| Multifocality                          |                    |                    | 0.363   |
| Single                                 | 85 (80.2)          | 349 (83.9)         |         |
| Multiple                               | 21 (19.8)          | 67 (16.1)          |         |
| Bilaterality                           |                    |                    | 0.129   |
| Bilateral                              | 74 (69.8)          | 320 (76.9)         |         |
| Unilateral                             | 32 (30.2)          | 96 (23.1)          |         |
| Tumor location                         |                    |                    | 0.003   |
| Upper                                  | 35 (33.3)          | 98 (23.6)          |         |
| Middle                                 | 41 (38.7)          | 162 (38.9)         |         |
| Low                                    | 21 (19.8)          | 142 (34.1)         |         |
| Isthmus                                | 9 (8.5)            | 14 (3.4)           |         |
| ETE                                     |                    |                    | <0.001  |
| Yes                                    | 23 (21.7)          | 31 (7.5)           |         |
| No                                     | 83 (78.30)         | 385 (92.5)         |         |
| Hashimoto’s thyroiditis                |                    |                    | 0.060   |
| Yes                                    | 18 (17.0)          | 107 (25.7)         |         |
| No                                     | 88 (83.0)          | 309 (74.3)         |         |
| Close to capsule                       |                    |                    | 0.026   |
| Yes                                    | 6 (5.7)            | 6(1.4)             |         |
| No                                     | 100 (94.3)         | 410 (98.6)         |         |
| CLNM                                   |                    |                    | <0.001  |
| Yes                                    | 89 (84.0)          | 124 (29.8)         |         |
| No                                     | 17 (16.0)          | 292 (70.2)         |         |
| LLNM                                   |                    |                    | <0.001  |
| Yes                                    | 32 (30.2)          | 9 (2.2)            |         |
| No                                     | 74 (69.8)          | 407 (97.8)         |         |
| Mean largest size of an LNM, cm       |                    |                    | <0.001  |
| Mean ± SD                              | 2.71 ± 1.07        | 2.12 ± 0.75        |         |
| Cancerous nodules                      |                    |                    | 1.000   |
| Yes                                    | 1 (0.9)            | 4(1.0)             |         |
| No                                     | 105 (99.1)         | 412 (99.0)         |         |
| Locoregional recurrence                |                    |                    | 0.028   |
| Yes                                    | 3 (2.8)            | 1 (0.2)            |         |
| No                                     | 103 (97.2)         | 415 (99.8)         |         |

DLN, Delphian lymph node; SD, standard deviation; LLNM, lateral lymph node metastasis; CLNM, central lymph node metastasis; ETE, extrathyroidal extension.
or upper 1/3 of the tumor [26]. Our research results are consistent with their finding. This finding indicates that the DLN mainly accepts lymphatic reflux from the upper-middle thyroid and isthmus. Tumors in the superior lobe of the thyroid are more prone to metastasize to the lateral lymph nodes [27, 28]. Skip metastasis rates range from 6.8 to 27.8% in PTC patients exhibiting LLNM [29, 30]. Here, the incidence of skip metastasis was 10%. These results suggest that skip metastases should be noted when tumors are located in the superior pole of the thyroid lobe, though the overall rate is low.

There is still controversy about prophylactic CLND for individuals with clinical lymph node-negative (cN0) disease. CLND should be performed for T3 or T4 tumors in individuals at high risk but should be avoided for low-risk patients who harbor T1 or T2 tumors. Fraser et al. found that only 14.7% of the cases were cN1, but 56.8% of the patients had CLNM [27]. Xue et al. also reported that the incidence of CLNM was 45.85% (713/1555), and males, age ≤45 years, ETE, and tumor size >1 cm were independently associated with the risk of CLNM among cN0 patients [31]. In our study, whether it was cN0 or cN+ patients, CLNM rates in the DLN-positive patients were greatly increased relative to those in DLN-negative individuals (73.5% vs. 26.6%, P < 0.001; 93.0% vs. 55.3%, P < 0.001). In addition, Chen et al. determined that DLNM was independently predictive of CCLNM in unilateral PTC by multivariate analysis [32]. In this study, 68 unilateral PTC patients underwent total thyroidectomy and bilateral CLND. Rates of CCLNM were significantly elevated among DLN-positive individuals (73.5% vs. 26.6%, P < 0.001; 93.0% vs. 55.3%, P < 0.001).

### Table 4: DLNM-related multivariate logistic regression analyses.

| Characteristics | 95% CI | OR | P value |
|-----------------|-------|----|---------|
| Sex             |       |    |         |
| Upper or isthmus|       |    |         |
| Close to capsule|       |    |         |
| ETE             |       |    |         |
| Tumor size > 1 cm|      |    |         |
| CLNM            |       |    |         |
| LLNM            |       |    |         |

### Table 5: Relationship between the DLN and CLNM.

|                | DLN-positive | DLN-negative | P value |
|----------------|--------------|--------------|---------|
| **Unilateral CLND (N = 372) n (%)** |              |              |         |
| CLNM Yes       | 49 (79.0)    | 84 (27.1)    | <0.001  |
| No             | 13 (21.0)    | 226 (72.9)   |         |
| No. of CLNM    |              |              |         |
| Mean ± SD      | 3.69 ± 2.38  | 2.06 ± 1.64  | <0.001  |
| >5             | 14 (28.6)    | 6 (7.1)      | 0.01    |
| 1–5            | 35 (71.4)    | 78 (92.9)    |         |

| **Bilateral CLND (N = 150) n (%)** |              |              |         |
| CLNM Yes       | 40 (93.0)    | 40 (37.4)    | <0.001  |
| No             | 3 (7.0)      | 67 (62.6)    |         |
| No. of CLNM    |              |              |         |
| Mean ± SD      | 5.90 ± 4.62  | 2.95 ± 3.35  | 0.002   |
| >5             | 19 (47.5)    | 1 (10.0)     | <0.001  |
| 1–5            | 21 (52.5)    | 36 (90.0)    |         |

### Table 6: Ipsilateral and contralateral CLNM in 68 unilateral PTC patients with total thyroidectomy and bilateral CLND.

|                | DLN-positive | DLN-negative | P value |
|----------------|--------------|--------------|---------|
| **CLNM**       |              |              |         |
| Ipsilateral Yes| 19 (95.0)    | 10 (20.8)    | <0.001  |
| No             | 1 (5.0)      | 38 (79.2)    |         |
| **Contraclateral** Yes| 10 (50.0)  | 3 (6.3)      | <0.001  |
| No             | 10 (50.0)    | 45 (93.8)    |         |

### Table 7: Relationship between DLN and LLNM.

|                | DLN-positive | DLN-negative | Total | P value |
|----------------|--------------|--------------|-------|---------|
| **CLNM**       |              |              |       |         |
| LLNM Yes       | 31 (93.9)    | 9 (69.2)     |       | 0.045   |
| No             | 2 (6.1)      | 4 (30.8)     |       |         |
| **No. of LLNM** |              |              |       |         |
| Mean ± SD      | 6.23 ± 4.50  | 3.89 ± 2.09  |       | 0.142   |

### Table 8: CLNM in cN0 or cN+ PTC.

|                | DLN-positive | DLN-negative | Total | P value |
|----------------|--------------|--------------|-------|---------|
| **CLNM in cN0 PTC n (%)** |              |              |       | <0.001  |
| Yes            | 36 (73.5)    | 98 (26.6)    | 134 (32.1) |       |
| No             | 13 (26.5)    | 271 (73.4)   | 284 (67.9) |       |
| **T stage**    |              |              |       | 0.011   |
| T1/T2          | 40 (81.6)    | 344 (93.2)   | 384 (91.9) |       |
| T3/T4          | 9 (18.4)     | 25 (6.8)     | 34 (8.1)  |       |

| **CLNM in 1 cN+ PTC n (%)** |              |              |       | <0.001  |
| Yes            | 53 (93.0)    | 26 (55.3)    | 79 (76.0) |       |
| No             | 4 (7.0)      | 21 (44.7)    | 25 (24.0) |       |
| **T stage**    |              |              |       | 0.900   |
| T1/T2          | 48 (84.2)    | 40 (85.1)    | 88 (84.6) |       |
| T3/T4          | 9 (15.8)     | 7 (14.9)     | 16 (15.4) |       |

DLN, Delphian lymph node; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; SD, standard deviation; No., number; SD, standard deviation.
pathologically after preventive lymph node dissection, which changes the TNM stage and postoperative treatment plan of PTC. Prophylactic central neck dissection in patients with low-risk tumors can reduce the recurrence rate. However, some scholars do not support routinely preventive central neck dissection because it increases the risk of patients with parathyroidism, transient or permanent recurrent laryngeal nerve injury, and chylous leakage.

Many studies have shown that the DLN can also predict LLNM in PTC patients [9, 28, 34, 35]. Here, DLNM was found to be closely associated with LLNM, with DLNM suggesting higher LLNM incidence rates and numbers. In addition, DLNM is more common when LLNM occurs, particularly in bilateral LLNM patients. As N1b corresponds to a high risk of disease recurrence [36], when there is clinical N1b disease, intraoperative assessment of DLN should be performed with caution. If necessary, DLN-positive patients should have all possible LLNs fully resected, including lymph nodes at levels II-V. Patients who have not undergone LLND should be carefully monitored after surgery.

There are some limitations to this analysis. First, this is a retrospective study, which may have potential selection bias. Second, the small number of LLND cases may lead to bias in our results. Third, the association between DLN and lymphatic vascular infiltration was not examined as the pathology department did not report lymphatic vascular infiltration. PTC is an indolent cancer, and the clinical significance of DLN warrants further verification by longer follow-up.

5. Conclusions

DLN metastasis in PTC patients is an indicator of a poor prognosis. Intraoperative rapid freezing for the DLN is highly recommended during thyroidectomy. CLND or even CCLND should be performed when DLNM is confirmed. Patients who have not undergone lymph node dissection should be followed up closely after surgery.

Data Availability

The data are available from the corresponding author upon request via email (9y140257@kust.edu.cn).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Qiumei Zuo and Xin Chen contributed equally to this work.

Acknowledgments

This work was supported by the Research Fund of Puer People’s Hospital (grant number 2021IEC016).

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] A. Y. Chen, A. Jemal, and E. M. Ward, “Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005,” Cancer, vol. 115, no. 16, pp. 3801–3807, 2009.
[3] E. Kebebew and O. H. Clark, “Differentiated thyroid cancer: “complete” rational approach,” World Journal of Surgery, vol. 24, no. 8, pp. 942–951, 2000.
[4] S. M. Chow, S. C. K. Law, J. K. C. Chan et al., “Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality,” Cancer, vol. 98, no. 1, pp. 31–40, 2003.
[5] H. Mehanna, T. Al-Maqbili, B. Carter et al., “Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 8, pp. 2834–2843, 2014.
[6] M. A. Adam, J. Pura, P. Goffredo et al., “Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer,” Journal of Clinical Oncology, vol. 33, no. 21, pp. 2370–2375, 2015.
[7] X. M. Yu, Y. Wan, R. S. Sippel, and H. Chen, “Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18, 445 cases,” Annals of Surgery, vol. 254, no. 4, pp. 653–660, 2011.
[8] Y. Ito, C. Tomoda, T. Uruno et al., “Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid,” World Journal of Surgery, vol. 30, no. 1, pp. 91–99, 2006.
[9] E. M. Oh, Y. S. Chung, and Y. D. Lee, “Clinical significance of Delphian lymph node metastasis in papillary thyroid carcinoma,” World Journal of Surgery, vol. 37, no. 11, pp. 2594–2599, 2013.
[10] A. Ferlito, A. R. Shaha, and A. Rinaldo, “Prognostic value of Delphian lymph node metastasis from laryngeal and hypopharyngeal cancer,” Acta Oto-Laryngologica, vol. 122, no. 4, pp. 456–457, 2002.
[11] K. D. Olsen, L. W. DeSanto, and B. W. Pearson, “Positive Delphian lymph node: clinical significance in laryngeal cancer,” T Laryngoscopy, vol. 97, no. 9, pp. 1033–1037, 1987.
[12] N. G. Iyer, A. Kumar, I. J. Nixon et al., “Incidence and significance of Delphian node metastasis in papillary thyroid cancer,” Annals of Surgery, vol. 253, no. 5, pp. 988–991, 2011.
[13] J. D. Isaacs, C. I. Lundgren, S. B. Sidhu, M. S. Sywak, P. J. Edhouse, and L. W. Delbridge, “The Delphian lymph node in thyroid cancer,” Annals of Surgery, vol. 247, no. 3, pp. 477–482, 2008.
[14] G. Zheng, H. Zhang, S. Hao et al., “Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis,” Oncotarget, vol. 8, no. 34, pp. 57089–57098, 2017.
[15] J. D. Isaacs, T. P. W. McMullen, S. B. Sidhu, M. S. Sywak, B. G. Robinson, and L. W. Delbridge, “Predictive value of the Delphian and level VI nodes in papillary thyroid cancer,” ANZ Journal of Surgery, vol. 80, no. 11, pp. 834–838, 2010.
[16] Y. Zhu, J. Lin, Y. Yan et al., “Delphian lymph node metastasis is a novel indicator of tumor aggressiveness and poor
prognosis in papillary thyroid cancer,” *Journal of Surgical Oncology*, vol. 123, no. 7, pp. 1521–1528, 2021.

[17] Y. Yan, Y. Wang, N. Liu et al., “Predictive value of the Delphian lymph node in cervical lymph node metastasis of papillary thyroid carcinoma,” *European Journal of Surgical Oncology*, vol. 47, no. 7, pp. 1727–1733, 2021.

[18] B. R. Haugen, E. K. Alexander, K. C. Bible et al., “American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer,” *Thyroid*, vol. 26, no. 1, pp. 1–133, 2016.

[19] Z. Y. Rui, Y. Liu, W. Zheng et al., “A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis,” *Clinical and Experimental Medicine*, vol. 21, no. 2, pp. 277–286, 2021.

[20] Y. Ito, M. Fukushima, C. Tomoda et al., “Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment,” *Endocrine Journal*, vol. 56, no. 6, pp. 759–766, 2009.

[21] I. Sugitani, N. Kasai, Y. Fujimoto, and A. Yanagisawa, “A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period,” *Surgery*, vol. 135, no. 2, pp. 139–148, 2004.

[22] J. Zhu, R. Huang, P. Yu et al., “Clinical implications of Delphian lymph node metastasis in papillary thyroid carcinoma,” *Gland Surgery*, vol. 10, no. 1, pp. 73–82, 2021.

[23] W. W. Kim, S. I. Yang, J. H. Kim, Y. S. Choi, Y. H. Park, and S. K. Kwon, “Experience and analysis of Delphian lymph node metastasis in patients with papillary thyroid carcinoma,” *World Journal of Surgical Oncology*, vol. 10, no. 1, p. 226, 2012.

[24] Y. C. Lee, S. Y. Shin, K. H. Kwon, and Y. G. Eun, “Incidence and clinical characteristics of praearyngeal lymph node metastasis in papillary thyroid cancer,” *European Archives of Oto-Rhino-Laryngology*, vol. 270, no. 9, pp. 2547–2550, 2013.

[25] L. Chen, Y. Zhu, K. Zheng et al., “The presence of cancerous nodules in lymph nodes is a novel indicator of distant metastasis and poor survival in patients with papillary thyroid carcinoma,” *Journal of Cancer Research and Clinical Oncology*, vol. 143, no. 6, pp. 1035–1042, 2017.

[26] Y. J. Chai, S. J. Kim, J. Y. Choi, D. H. Koo, K. E. Lee, and Y. K. Youn, “Papillary thyroid carcinoma located in the isthmus or upper third is associated with delphian lymph node metastasis,” *World Journal of Surgery*, vol. 38, no. 6, pp. 1306–1311, 2014.

[27] S. Fraser, N. Zaidi, O. Norlen et al., “Incidence and risk factors for occult level 3 lymph node metastases in papillary thyroid cancer,” *Annals of Surgical Oncology*, vol. 23, no. 11, pp. 3587–3592, 2016.

[28] T. T. Zhang, X. Z. Qi, J. P. Chen et al., “The association between tumor’s location and cervical lymph nodes metastasis in papillary thyroid cancer,” *Gland Surgery*, vol. 8, no. 5, pp. 557–568, 2019.

[29] X. Nie, Z. Tan, and M. Ge, “Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice,” *BMC Cancer*, vol. 17, no. 1, p. 702, 2017.

[30] H. Zhao, T. Huang, and H. Li, “Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer,” *Surgery*, vol. 166, 2019.

[31] S. Xue, P. Wang, J. Liu, R. Li, L. Zhang, and G. Chen, “Prophylactic central lymph node dissection in cN0 patients with papillary thyroid carcinoma: a retrospective study in China,” *Asian Journal of Surgery*, vol. 39, no. 3, pp. 131–136, 2016.

[32] Q. Chen, X. H. Zou, T. Wei, Q. S. Huang, Y. H. Sun, and J. Q. Zhu, “Prediction of ipsilateral and contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma: a retrospective study,” *Gland Surgery*, vol. 4, no. 4, pp. 288–294, 2015.

[33] T. A. Moo, J. McGill, J. Allendorf, J. Lee, T. Fahey, and R. Zarnegar, “Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma,” *World Journal of Surgery*, vol. 34, no. 6, pp. 1187–1191, 2010.

[34] Z. Tan, M. H. Ge, C. M. Zheng, Q. L. Wang, X. L. Nie, and L. H. Jiang, “The significance of Delphian lymph node in papillary thyroid cancer,” *Asia-Pacific Journal of Clinical Oncology*, vol. 13, no. 5, pp. e389–e393, 2017.

[35] J. Huang, W. Sun, H. Zhang et al., “Use of Delphian lymph node metastasis to predict central and lateral involvement in papillary thyroid carcinoma: a systematic review and meta-analysis,” *Clinical Endocrinology*, vol. 91, no. 1, pp. 170–178, 2019.

[36] G. Sapuppo, F. Palermo, M. Russo et al., “Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome,” *Journal of Endocrinological Investigation*, vol. 40, no. 12, pp. 1355–1363, 2017.